Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
出版年份 2021 全文链接
标题
Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
作者
关键词
-
出版物
JAMA Network Open
Volume 4, Issue 5, Pages e218065
出版商
American Medical Association (AMA)
发表日期
2021-05-08
DOI
10.1001/jamanetworkopen.2021.8065
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States
- (2020) Robert Haddad et al. JOURNAL OF MEDICAL ECONOMICS
- Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040)
- (2019) Sara I. Pai et al. Journal for ImmunoTherapy of Cancer
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
- (2018) Robert L. Ferris et al. ORAL ONCOLOGY
- Assessment of costs associated with adverse events in patients with cancer
- (2018) William Wong et al. PLoS One
- Unknown
- (2018) CA-A CANCER JOURNAL FOR CLINICIANS
- Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
- (2018) Ezra E W Cohen et al. LANCET
- Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France
- (2018) Christos Chouaid et al. LUNG CANCER
- Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma
- (2018) Bin Wu et al. Journal for ImmunoTherapy of Cancer
- Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma
- (2017) Christine G. Kohn et al. JOURNAL OF CLINICAL ONCOLOGY
- Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- (2017) Kathryn R Tringale et al. JNCI-Journal of the National Cancer Institute
- Cost‐Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma
- (2017) Mahdi Zargar et al. ONCOLOGIST
- Cost-effectiveness of nivolumab for recurrent or metastatic head and neck cancer☆
- (2017) Matthew C. Ward et al. ORAL ONCOLOGY
- Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- (2017) Kathryn R Tringale et al. JNCI-Journal of the National Cancer Institute
- Health state utilities in non-small cell lung cancer: An international study
- (2016) Beenish Nafees et al. Asia-Pacific Journal of Clinical Oncology
- Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses
- (2016) Gillian D. Sanders et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Unknown
- (2016) LARYNGOSCOPE
- The Cost of Hospice Services in Terminally Ill Patients With Head and Neck Cancer
- (2015) Laura M. Enomoto et al. JAMA Otolaryngology-Head & Neck Surgery
- Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold
- (2014) Peter J. Neumann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Economic Burden of Adverse Events in Patients With Metastatic Renal Cell Carcinoma
- (2013) May Hagiwara et al. CLINICAL THERAPEUTICS
- Cost-effectiveness of systemic therapies for metastatic pancreatic cancer
- (2013) V.C. Tam et al. Current Oncology
- CONSOLIDATED HEALTH ECONOMIC EVALUATION REPORTING STANDARDS (CHEERS) STATEMENT
- (2013) Don Husereau et al. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE
- Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data
- (2013) Nicholas R. Latimer MEDICAL DECISION MAKING
- Cost Effectiveness of Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in Ireland
- (2013) Dawn Lee et al. Applied Health Economics and Health Policy
- Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
- (2012) Patricia Guyot et al. BMC Medical Research Methodology
- Model Parameter Estimation and Uncertainty Analysis
- (2012) Andrew H. Briggs et al. MEDICAL DECISION MAKING
- Projections of the Cost of Cancer Care in the United States: 2010-2020
- (2011) A. B. Mariotto et al. JNCI-Journal of the National Cancer Institute
- Economic burden of toxicities associated with metastatic colorectal cancer treatment regimens containing monoclonal antibodies
- (2011) Chakkarin Burudpakdee et al. JOURNAL OF MEDICAL ECONOMICS
- Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study
- (2010) Kathleen M Beusterien et al. Health and Quality of Life Outcomes
- Health State Utility Scores for Cancer-Related Anemia through Societal and Patient Valuations
- (2008) Andrew Lloyd et al. VALUE IN HEALTH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started